Welcome to our dedicated page for Carisma Therapeutics news (Ticker: $CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Carisma Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Carisma Therapeutics's position in the market.
Carisma Therapeutics Inc. (Nasdaq: CARM) presented groundbreaking preclinical data at ASGCT 2024, showcasing the efficacy of engineered macrophages in reducing liver fibrosis. The therapy demonstrated significant reductions in fibrosis in liver and lung models, offering promising solutions for metabolic dysfunction-associated diseases. Carisma plans to nominate a development candidate for its liver fibrosis program in early 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.
Carisma Therapeutics Inc. (Nasdaq: CARM) has appointed Dr. Eugene P. Kennedy as the Chief Medical Officer. Dr. Kennedy, with over 15 years of experience in clinical and industry settings, will oversee Carisma's clinical development, regulatory, and medical affairs functions. His expertise in oncology and immuno-oncology is expected to positively impact the organization and advance their clinical program and pipeline.
